Company intelligence / Profile preview

Ayana Pharma

Ownership: Private
Development stage: Commercial

Overview

Lead product LC101 (Doxorubicin-HCl Liposomal Injection) is FDA-approved for treatment of Ovarian Cancer, Multiple Myeloma and AIDS-related Kaposi's Sarcoma. The product was launched in the US by Padagis (Perrigo) in October 2021[1][3].

Therapeutic areas: Oncology
Modalities: Liposomal therapeutics
Industry: Biotech

Drug pipeline

1 asset

doxorubicin hydrochloride

Commercial

Indications: Ovarian cancer, Multiple myeloma, AIDS-related Kaposi's sarcoma

Partnerships

Strategic agreement with tier 1 pharma company for commercialization of LC101 in the U.S. market[1]Padagis (Perrigo) for US launch of LC101[3]Scinai Immunotherapeutics (CDMO business unit) for drug development and cGMP manufacturing services[5]

Beyond the preview

Go deeper on Ayana Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ayana Pharma.

Explore the full profile